tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Keymed Biosciences’ Stapokibart Wins Approval in China

Keymed Biosciences’ Stapokibart Wins Approval in China

Keymed Biosciences, Inc. (HK:2162) has released an update.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Keymed Biosciences Inc. has announced the approval of their new drug, Stapokibart, by China’s National Medical Products Administration for treating moderate-to-severe atopic dermatitis in adults. This first domestically manufactured IL-4R α antibody drug showed promising results in Phase III clinical trials, meeting primary endpoints and exhibiting a good safety profile. However, the company cautions shareholders that there’s no guarantee of successful commercialization.

For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1